ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2371

KBP-5074, a Nonsteroidal Mineralocorticoid Receptor Antagonist, Reduces Urine Albumin-to-Creatinine Ratio and the Risk of Hyperkalemia in an Animal Model of CKD

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1800 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Jaisser, Frederic, Centre de Recherche des Cordeliers, Paris, Île-de-France, France
  • Jinrong, Liu, Kbp Biosciences Co Ltd, Jinan, China
  • Chi, Shuangshuang, Kbp Biosciences Co Ltd, Jinan, China
  • Wang, Ping, Kbp Biosciences Co Ltd, Jinan, China
  • Tan, Judy, Kbp Biosciences Co Ltd, Jinan, China
  • Benn, Vincent, KBP Biosciences USA Inc, Princeton, New Jersey, United States
  • Yang, Y. Fred, KBP Biosciences USA Inc, Princeton, New Jersey, United States
  • Zhang, Jay, KBP Biosciences USA Inc, Princeton, New Jersey, United States

Group or Team Name

  • KBP Biosciences USA Inc

KBP-5074 is a novel non-steroidal mineralocorticoid receptor antagonist (MRA) being developed for uncontrolled hypertension and advanced chronic kidney disease. The primary objective of this study was to evaluate KBP-5074 and eplerenone for renal protection against aldosterone-mediated renal disease in a uninephrectomized Sprague-Dawley (SD) rat model.


Uninephrectomized rats were maintained on a 6% high salt diet, and received aldosterone infusion for 27 days. Urinary albumin to creatinine ratio (UACR), urinary Na+/K+, and serum K+ were assessed following 14 and 27 days of treatment. Blood samples were collected on days 1 and 26 to determine PK profiles. PK/PD analyses were performed on urinary Na+/K+ ratio, UACR, and serum K+.


KBP-5074 (1, 3, and 10 mg/kg/day) significantly reduced UACR by 77%, 96%, and 99% respectively on day 14, and 50%, 86% and 99% respectively on day 26 in a dose dependent manner, while eplerenone (100 and 900 mg/kg/day) reduced UACR by 40% and 99% respectively on day 26. PK/PD analysis of Urinary Na+/K+ ratio indicated that KBP-5074 was approximately 18-fold more efficacious than eplerenone. Analysis of UACR and serum K+ indicated that the EC50 for serum K+ increase and UACR reduction was 538 nM and 22.0 nM respectively for KBP-5074, and 666 nM and 1071 nM respectively for eplerenone, resulting in a therapeutic index (TI) against hyperkalemia of 24.24 for KBP-5074 vs 0.62 for eplerenone. Thus, the TI against hyperkalemia of KBP-5074 was 39-fold superior to that of eplerenone, suggesting that the non-steroidal MRA KBP-5074 may present an extended therapeutic window as compared to the steroidal MRA eplerenone.


KBP-5074 demonstrated a significant effect on UACR reduction with less risk for hyperkalemia compared to eplerenone in a rat model of nephropathy.


  • Commercial Support